-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroThera Labs expands U.S. patent portfolio in collaboration with Clearmind Medicine

PUBT·09/23/2026 12:16:36
Listen to the news
NeuroThera Labs expands U.S. patent portfolio in collaboration with Clearmind Medicine
  • NeuroThera expanded its collaboration with Clearmind Medicine to build U.S. patent coverage for PEA combinations with psychedelic-derived compounds.
  • Three published U.S. patent applications cover PEA used with LSD, ketamine, or ibogaine for potential mental health, pain, or substance use indications.
  • Work follows an earlier U.S. patent application from the collaboration covering an MDMA-PEA combination targeting PTSD, anxiety, or eating disorders.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurothera Labs Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202609230815TNWSWRCACNPR_____1LYzFXY0a) on September 23, 2026, and is solely responsible for the information contained therein.